Therapy Areas: Autoimmune
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
4 September 2026 - Kali Therapeutics, a clinical-stage biotechnology company focused on new therapies for autoimmune and inflammatory diseases, announced on Thursday that the US Food and Drug Administ...
Lilly to acquire Merida Biosciences in USD2.875bn deal
31 August 2026 - US pharmaceutical company Eli Lilly and Company (NYSE: LLY) on Monday announced that it has agreed to acquire Merida Biosciences, Inc., a biotechnology business developing precision b...
FDA approves Johnson & Johnson's IMAAVY (nipocalimab-aahu) to treat warm autoimmune haemolytic anaemia
25 August 2026 - Healthcare products company Johnson & Johnson (NYSE:JNJ) announced on Monday that the US Food and Drug Administration (FDA) has approved IMAAVY (nipocalimab-aahu) for the treatmen...
Antengene's Phase I study of ATG-201 in B cell-related autoimmune diseases approved in Australia
25 August 2026 - Commercial-stage biotech company Antengene Corporation Limited (SEHK:6996.HK) announced on Monday that the Phase I ATTRACT study of its proprietary ATG-201, a CD19/CD3 bispecific T-ce...
Alfasigma to acquire Nordic Pharma, expanding specialty care portfolio
11 August 2026 - Italian pharmaceutical company Alfasigma S.p.A. announced on Tuesday that it has entered into an agreement with SEVER Life Sciences B.V. to acquire 100% of Nordic Group B.V. and its s...
European Commission approves RINVOQ for severe alopecia areata
29 July 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) said on Wednesday it has received European Commission approval for RINVOQ (upadacitinib) to treat adults and adolescents aged 12 and ove...